Results 21 to 30 of about 862,573 (173)

Individualized active surveillance for carbapenem-resistant microorganisms using Xpert Carba-R in intensive care units

open access: yesScientific Reports, 2023
Carbapenem antibiotics are widely used in ICU, and the prevalence of carbapenem-resistant microorganisms (CRO) has increased. This study aimed to assess the role of individualized active surveillance using Xpert Carba-R of carbapenem resistance genes on ...
Shuliang Zhou   +7 more
doaj   +1 more source

Carbapenem Resistance in Non-Fermentative Gram-Negative Bacilli Isolated from Intensive Care Unit Patients of a Referral Hospital

open access: yesJournal of Nepal Health Research Council, 2021
Background: Non-fermentative Gram-negative bacilli or non-fermenters are opportunistic pathogens associated with serious infections in intensive care unit patients.
Santosh Kumar Yadav   +4 more
doaj   +1 more source

Polyphasic characterization of carbapenem-resistant Klebsiella pneumoniae clinical isolates suggests vertical transmission of the blaKPC-3 gene [PDF]

open access: yes, 2021
Carbapenem-resistant Klebsiella pneumoniae are a major global threat in healthcare facilities. The propagation of carbapenem resistance determinants can occur through vertical transmission, with genetic elements being transmitted by the host bacterium ...
Lameiras, Catarina,   +32 more
core   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli

open access: yesAntibiotics, 2021
The emergence of carbapenem-resistant Enterobacterales (CRE) seriously limits treatment options for bacterial infections. Combined drugs are an effective strategy to treat these resistant strains.
Hye-Rim Kim, Yong-Bin Eom
doaj   +1 more source

Structure and Biosynthesis of Mangotoxin Produced by the Plant Pathogen Pseudomonas syringae

open access: yesAngewandte Chemie, EarlyView.
The structure of mangotoxin remained elusive for over two decades. Here, mangotoxin was isolated from the native producer, Pseudomonas syringae pv. syringae, and was determined to be an alkyne‐containing dipeptide. Mangotoxin inhibited the growth of multidrug‐resistant human pathogen Klebsiella pneumoniae.
Alexis H. Murray   +4 more
wiley   +2 more sources

Distribution of 121 carbapenem-resistant isolates.

open access: yes, 2023
Distribution of 121 carbapenem-resistant isolates.
Shiwen Sun (1596106)   +15 more
core   +1 more source

Tree diagram for carbapenem-resistant Enterobacterales infections.

open access: yes, 2022
Tree diagram for carbapenem-resistant Enterobacterales infections.
Nicholas Graves (258283)   +8 more
core   +1 more source

Risk factors and outcome associated with coinfection with carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumanii: a descriptive analysis

open access: yesFrontiers in Cellular and Infection Microbiology, 2023
BackgroundNearly 30% of patients infected with carbapenem-resistant Klebsiella pneumoniae (CRKP) were previously shown to be coinfected with carbapenem-resistant Pseudomonas aeruginosa (CRPA) or Acinetobacter baumannii (CRAB).
Anthony Sophonsri   +6 more
doaj   +1 more source

First report of carbapenem-resistant Providencia stuartii in Saudi Arabia

open access: yesNew Microbes and New Infections, 2018
We present the case of 31-year-old man who developed hospital-acquired pneumonia in the intensive care unit. Pathogens were identified to be carbapenem-resistant isolates of Providencia stuartii and Klebsiella pneumoniae.
M. Abdallah   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy